Podcasts about Biomarker

In dieser Folge spreche ich mit Dr. Ulrich Bauhofer – Deutschlands bekanntestem Ayurveda-Arzt – über die Schnittmengen von Ayurveda und ganzheitlicher Präventionsmedizin. Wir diskutieren, wie traditionelle Konzepte mit aktueller Longevity-Forschung zusammenfinden, wo evidenzbasierte Daten vorliegen und wo Beobachtung und Erfahrung tragen. Außerdem geht es um personalisierte Lebensstilstrategien, Rasayanas, Ernährung, Schlaf, Bewegung – und die oft unterschätzte Rolle von Sinn und Glück für Healthy Longevity. In dieser Folge sprechen wir u.a. über folgende Themen: - Warum braucht unser Gesundheitssystem einen Paradigmenwechsel hin zur Prävention? - Wie lassen sich Doshas als „Bioprogramme“ in heutige wissenschaftliche Sprache übersetzen? - In welchem Maße sind Dosha-Prägungen genetisch versus lebensstilabhängig? - Welche Schnittmengen bestehen zwischen mitochondrialer Energieproduktion und dem Pitta-Konzept? - Wo liegen Chancen und Grenzen von Repurposed Drugs (z. B. Metformin, Rapamycin) in der Prävention? - Wie bewerten wir Evidenz: jahrtausendelange Erfahrung vs. aktuelle Studien mit Bioverfügbarkeit und Langzeiteffekten? - Was bedeutet „Ama“ im biomedizinischen Verständnis (Entzündungen, Umweltgifte, Zellmüll, Leaky Gut)? - Welche Ernährungsempfehlungen sind typgerecht sinnvoll – und wo kollidieren sie mit moderner Ernährungsforschung? - Warum betont Ayurveda heißes Wasser und welche physiologischen Effekte werden angenommen? - Welche Bedeutung haben Schlaf, Sinn und Beziehungen für gesunde Langlebigkeit – jenseits reiner Biomarker? - Was können Hörer:innen sofort umsetzen, um „aktiv zu verjüngen“ – evidenzbasiert und alltagsnah? Weitere Informationen zu Dr. Ulrich Bauhofer findest du hier: https://www.drbauhofer.de/ Du interessierst dich für Gesunde Langlebigkeit (Longevity) und möchtest ein Leben lang gesund und fit bleiben, dann folge mir auch auf den sozialen Kanälen bei Instagram, TikTok, Facebook oder YouTube. https://www.instagram.com/nina.ruge.official https://www.tiktok.com/@nina.ruge.official https://www.facebook.com/NinaRugeOffiziell https://www.youtube.com/channel/UCOe2d1hLARB60z2hg039l9g Disclaimer: Ich bin keine Ärztin und meine Inhalte ersetzen keine medizinische Beratung. Bei gesundheitlichen Fragen wende dich bitte an deinen Arzt/deine Ärztin. STY-229

"It's critical to identify those mutations found that are driving the cancer's growth and guide the personalized treatment based on those results. And important to remember, too, early testing is crucial for patients with non-small cell lung cancer (NSCLC). In studies, it has been found to be associated with improved survival outcomes and reduced mortality," ONS member Vicki Doctor, MS, BSN, BSW, RN, OCN®, precision medicine director at the City of Hope Atlanta, GA, Chicago, IL, and Phoenix, AZ, locations, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the oncology nurse's role in NSCLC biomarker testing. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Lilly Oncology and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities Episode 238: Cancer Genomics for Every Oncology Nurse Episode 157: Biomarker Testing Improves Outcomes for Patients With Non-Small Cell Lung Cancer ONS Voice articles: Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Only a Third of Patients With Advanced Cancer Get Biomarker Testing, Limiting Use of Potentially Effective Precision Therapies Precision Medicine in Lung Cancer: How Comprehensive Testing Optimizes Patient Outcomes Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Using Nurse Navigators to Improve Timeliness of Biomarker Testing for Non-Small Cell Lung Cancer Oncology Nursing Forum article: Precision Medicine Testing and Disparities in Health Care for Individuals With Non-Small Cell Lung Cancer: A Narrative Review Other ONS resources: Best Practices for Biomarker Testing in Non-Small Cell Lung Cancer: A Case Study Genomics and Precision Oncology Learning Library Genomics Case Study: Precision Medicine in the Setting of Metastatic Non-Small Cell Lung Cancer Biomarker Database (refine by non-small cell lung cancer) Genomic Biomarkers Huddle Card Targeted Therapy Huddle Card National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "These biomarkers are used to provide information about cancer's characteristics or behavior. In oncology precision medicine specifically, molecular tests can help with diagnosing a cancer that is maybe an unknown primary. It can help with monitoring response to therapy, detect recurrence of disease before other tests can find that, predict prognosis or how aggressive the cancer may be, and guide treatment decisions for targeted therapies." TS 3:14 "Some of the key biomarkers recommended by the National Comprehensive Cancer Network (NCCN) to be tested in patients who have NSCLC are EGFR, ALK, KRAS, BRAF, MET exon 14 skipping mutation, HER2 which is a protein expression from an ErbB protein, PD-L1 which is a protein expression that's used to guide immunotherapy choices, and then finally there are three fusions: ROS1, RET, and NTRK. [These] are pretty rare but really important to be tested for in patients who have NSCLC." TS 3:46 "Another important challenge for nurses related to this topic is that these results may not reveal a targeted mutation for the patient and that could be very disappointing. So, being able to provide that emotional support to a patient if they have that result … you can actually reinforce with them that if [they] go onto another treatment that the physician decides to put [them] on, the tumor can change. New pathogenic variants can develop based on the treatment that they're getting, and another test can be done. And maybe at that time—a new biomarker that could be targeted—we'd be seeing on the new test." TS 7:32  "Another circumstance we didn't talk about yet is that maybe the result came back saying that the quality was not sufficient. And sometimes that happens, but that doesn't mean that we're at the end of the road, necessarily. So, you could explain to the patient that that may mean that possibly, a new biopsy would be ordered by the physician. Or if a new biopsy or another tissue sample is not available, then maybe the physician would pivot to sending a blood specimen for the molecular testing. So that would definitely be a way [nurses] could support their patients." TS 11:52 "In the case of patients with NSCLC, early testing is so important. So, advocating for that prompt biomarker testing to be done, making sure that it's comprehensive, that it's actually looking for all of those—I think it was 12 biomarkers—that I mentioned earlier. That this testing is done as soon as possible after diagnosis or progression. Something that I talk about all the time—personalized care, precision medicine—really matters. So, tailoring treatments for patients based on the biology of the tumor that's driving the cancer's growth is really crucial if you're going to be working as an oncology nurse. Another crucial thing, because it's changing so quickly, is to stay informed." TS 16:23

Chronische, „stille“ Entzündung (Inflammaging) bleibt oft unbemerkt – mit Folgen für Energie, Fokus, Stoffwechsel und Gefäße. In dieser Folge sprechen über sinnvolle Biomarker, typische Ursachen von Insulinresistenz bis Mundhöhle – und diskutieren Ernährung, Bewegung, Schlaf und wenige, solide Supplements.

Host: Jennifer Caudle, DO Guest: Samuel Klempner, MD Guest: Nataliya Uboha, MD, PhD Testing for biomarkers like PD-L1, HER2, claudin 18.2, and FGFR2b is reshaping our approach to first-line therapy in advanced gastric and gastroesophageal junction cancers. Alongside biomarker profiling, we must also weigh practical considerations around efficacy, toxicity, and patient-specific factors when selecting treatment. Joining Dr. Jennifer Caudle to explore how we can optimize our first-line treatment selection are Drs. Samuel Klempner and Dr. Nataliya Uboha. Dr. Klempner is an Associate Professor of Medicine at Harvard Medical School, and Dr. Uboha is an Associate Professor in the Division of Hematology and Oncology in the Department of Medicine at the University of Wisconsin.

Was ist an der hypertrophen Kardiomyopathie (HCM) besonders und was ändert sich durch die neue Behandlung mit Myosininhibitoren? In dieser Folge von KardioBeat sprechen Prof. Dr. Fabian Knebel und Prof. Dr. David Duncker über die aktuelle Diagnose, Behandlung und Nachsorge dieser häufigen Erkrankung.

Chronisch-entzündliche Darmerkrankungen wie Morbus Crohn oder Colitis ulcerosa sind bislang unheilbar. Warum ist das so? Welche Rolle spielen Genetik, Mikrobiom und Immunzellen? Und wie können Biomarker und Multiomics helfen, Therapien künftig individuell anzupassen? Darüber spricht Prof. Dr. Philip Rosenstiel von der Christian-Albrechts-Universität zu Kiel in dieser Folge und zeigt, wie Biomarker und Multiomics die personalisierte Therapie voranbringen können.

Klinisch Relevant ist Dein Wissenspartner für das Gesundheitswesen. Drei mal pro Woche, nämlich dienstags, donnerstags und samstags, versorgen wir Dich mit unserem Podcast und liefern Dir Fachwissen für Deine klinische Praxis. Weitere Infos findest Du unter https://klinisch-relevant.de

Joel Jamison is back for another deep dive, and this episode is packed with actionable insights, personal health revelations, and answers to your burning questions. We cover everything from the legitimacy of new health tech to Joel's ongoing journey with a shocking calcium score and what he's doing about it.If you have a family history of heart disease, use wearable tech, or are just focused on optimizing your health and longevity, this conversation is for you.TIMESTAMPS:00:00:00 - Introduction & The Random Test00:01:38 - The Quest Bar Founder Funding Cancer Research00:02:47 - New AirPods & Measuring Heart Rate/HRV Through Your Ear00:05:04 - HRV: Training to Win vs. Training for Longevity00:06:09 - Waking Up at 4:30 AM vs. 6:30 AM: Impact on Sleep & HRV00:09:45 - ADHD Medications, Supplements, and Their Effects on HRV00:10:56 - The Search for Large-Scale HRV Data00:11:56 - Is HRV Still "Cutting Edge"?00:13:38 - What's Better Than HRV? (The "Dream" Biomarker)00:14:59 - Can You Measure HRV Without a Smart Device?00:15:53 - Cannabis Use and Its Drastic Impact on HRV00:17:59 - Best Practices for Accurate HRV Measurement (Morpheus)00:18:52 - DEEP DIVE: Joel's Shocking Heart Health Journey00:29:07 - Listener Case: High LP(a) and Stubbornly Low HRV00:30:36 - Listener Case: Low Oura Ring HRV but Excellent Other Markers00:32:56 - The Problem with "Cardiovascular Age" Metrics00:34:11 - How Accurate Are Garmin & Oura Ring VO2 Max Estimates?00:37:51 - The Credibility Problem with "Biological Age" & Oral Peptides00:40:07 - Update: Joel's Latest CCTA & Calcium Score Results00:41:32 - Analyzing the Scans: Radiologist vs. Cleerly AIIf you have a family history of heart disease, this conversation is a must-watch. Listen to the full podcast now.If you enjoyed this don't forget to subscribe and hit the bell so you don't miss our next deep-dive conversation.

Exploring biomarker testing in clinical research

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. Following the 2025 Alzheimer's Association International Conference (AAIC), Rebecca Edelmayer, PhD, outlines the Alzheimer's Association's first clinical practice guidelines for using blood-based biomarkers (BBMs) in the diagnostic workup of suspected Alzheimer's disease within specialized care. She explains the guideline mission, how tests were evaluated for accuracy, and when BBMs should serve as triage versus confirmatory tools relative to CSF and PET. Edelmayer details current scope limits (cognitively impaired patients in specialty settings), cautions against overextending to primary care or unimpaired populations, and previews the education roll-out—executive summaries, micro-learning modules, and shared decision-making resources. She closes with research priorities: stronger peer-reviewed reporting, broader validation across diverse populations and settings, and building an equitable pathway that leverages BBMs to speed accurate diagnosis and treatment access. Looking for more Alzheimer & dementia discussion? Check out the NeurologyLive® Alzheimer & dementia clinical focus page. Episode Breakdown: 1:05 – Understanding the purpose and mission behind new blood-based biomarker guidelines 2:05 – Key recommendations and defining triage vs confirmatory blood-based biomarker use 3:15 – Clinical precautions and where blood-based biomarkers are appropriate today 5:30 – Neurology News Minute 7:45 – Educating clinicians on implementing BBMs in specialty care 10:15 – Research priorities to strengthen evidence and ensure equity The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease B-Cell Modulator Obexelimab Shows Pronounced Relapse Reduction in Phase 2 MoonStone Trial Subcutaneous Efgartigimod Shows Efficacy in Phase 2 ALKIVIA, Phase 3 ADAPT SERON Trials Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Longevity isn't luck; it's data, discipline, and daily tracking. Dr. Michael Lustgarten shows us what it really takes to measure, master, and extend human healthspan through science and self-experimentation.Dr. Lustgarten has spent two decades turning his body into a living lab. With over 35 published papers, a TED Talk on personalized health, and his book Microbial Burden, he's on a mission to quantify everything from diet and biomarkers to blood chemistry and gut health.We discuss why real longevity starts with mastering the basics: diet, exercise, and lean body composition, and how testing, tracking, and AI-driven analysis are changing what's possible for human lifespan. He opens up about his personal story, how a book by Dr. Roy Walford changed his life, and why he believes conquering aging is both a philosophy and a data challenge."I'm either gonna figure this stuff out and the world will see how smart I think I am, or I'm gonna die trying." - Dr. Michael LustgartenSupport the show and get 50% off MCT oil with free shipping—just leave us a review on iTunes and let us know!https://podcasts.apple.com/us/podcast/live-beyond-the-norms/id1714886566 Mentioned In This Episode:- Roy Walford's Beyond the 120 Year Diet: https://a.co/d/7TmBtuT - Microbial Burden: A Major Cause Of Aging And Age-Related Disease: https://a.co/d/7VR0jXg About Dr. Michael Lustgarten:Dr. Michael Lustgarten is a PhD physiologist specializing in aging, metabolomics, and the gut microbiome. He has published over 35 papers and delivered a TED Talk on evidence-based personalized health. He's the author of Microbial Burden: A Major Cause Of Aging And Age-Related Disease and runs the YouTube channel Conquer Aging or Die Trying, where he documents his journey to slow aging through rigorous self-experimentation. Michael offers personalized coaching through Patreon, helping people optimize their biomarkers through data-driven interventions.Connect with Dr. Michael Lustgarten:- Website: https://michaellustgarten.com/ - YouTube: https://www.youtube.com/@conqueragingordietrying123 - Patreon: https://www.patreon.com/MichaelLustgartenPhD - Instagram: https://www.instagram.com/conqueraging122/ Connect with Chris Burres:- Website: https://www.myvitalc.com/ - Website: http://www.livebeyondthenorms.com/ - Instagram: https://www.instagram.com/chrisburres/ - TikTok: https://www.tiktok.com/@myvitalc - LinkedIn: https://www.linkedin.com/in/chrisburres/ 

Join Tara Crawford-Parks, PhD, Director for Translational R&D and Product Enablement at DNA Genotek, to explore the potential of first void urine biomarkers in clinical diagnostics. Discover how this non-invasive sampling method is transforming HPV screening and opening new possibilities for early disease detection in oncology and infectious diseases. Learn about the science behind first void urine collection, its advantages over traditional sampling methods, and how innovative devices like the Colli-Pee™ are supporting more accessible healthcare for underserved populations worldwide.

In this episode, Eric Hardter and guest Kelsey Lenoch discuss recent US FDA developments, including leadership changes at CBER and CDER, staffing impacts on orphan product reviews, and the new Rare Disease Evidence Principles aimed at accelerating approvals for rare and ultra-rare conditions. They also explore evolving trial endpoints in oncology (including surrogate measures and ctDNA), transparency moves such as the public release of Complete Response Letters and the industry's reactions, updates on the National Priority Voucher Program, and the FDA Pre-Check initiative to boost domestic drug manufacturing. Tune in for an in-depth discussion offering timely updates and expert perspectives on what may be ahead for drug development stakeholders.

Guest: David Feller-Kopman, MD Cytology via thoracentesis remains the first-line approach for diagnosing malignant pleural effusion (MPE), yet its sensitivity is limited. leaving many patients undiagnosed or delayed in treatment. In this expert-led discussion, Dr. David Feller-Kopman explores the limitations of current diagnostic methods and the evolving role of biomarkers in enhancing both diagnostic accuracy and prognostic insight. Dr. Feller-Kopman is a Professor of Medicine at the Geisel School of Medicine at Dartmouth and the Chief of Pulmonary and Critical Care Medicine at Dartmouth-Hitchcock Medical Center, and he discussed this topic at the 2025 CHEST Annual Meeting.

Guest: David Feller-Kopman, MD Cytology via thoracentesis remains the first-line approach for diagnosing malignant pleural effusion (MPE), yet its sensitivity is limited. leaving many patients undiagnosed or delayed in treatment. In this expert-led discussion, Dr. David Feller-Kopman explores the limitations of current diagnostic methods and the evolving role of biomarkers in enhancing both diagnostic accuracy and prognostic insight. Dr. Feller-Kopman is a Professor of Medicine at the Geisel School of Medicine at Dartmouth and the Chief of Pulmonary and Critical Care Medicine at Dartmouth-Hitchcock Medical Center, and he discussed this topic at the 2025 CHEST Annual Meeting.

Harald Müller-Huesmann und David Liesenfeld ziehen Bilanz vom ESMO in Berlin: Langzeit-Follow-ups in molekularen Subgruppen, ctDNA-Stratifizierung, KI-Ansätze und die Implikationen kommender Zulassungen für Klinik und Forschung.

Jakob Nikolas Kather und Harald Müller-Huesmann diskutieren auf dem Europäischen Krebskongress in Berlin, wie KI die Onkologie verändert: von ChatGPT und AI Agents über KI-basierte Biomarker bis hin zu digitalen Datenplattformen. Ein Blick in die Zukunft zwischen Forschung, Klinik und Ethik.

Grip Strength: An Indispensable Biomarker For Older Adults Bohannon RW Clin Interv Aging. 2019;14:1681-1691. doi:10.2147/CIA.S194543 APTA Magazine article mentioned: https://www.apta.org/apta-magazine/2025/09/01/hands-on-grip-strength-as-a-measure-of-health Due to copyright laws, unless the article is open source we cannot legally post the PDF on the website for the world to download at will. Brought to you by our sponsors at: CSMi – https://www.humacnorm.com/ptinquest VALD MoveHealth - https://movehealth.me/ Learn more about/Buy Erik/Jason/Chris's courses – The Science PT Support us on the Patreons! Music for PT Inquest: “The Science of Selling Yourself Short” by Less Than Jake Used by Permission Other Music by Kevin MacLeod – incompetech.com: MidRoll Promo – Mining by Moonlight Koal Challenge – Sam Roux  

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Comprehensive-Biomarker-Testing-in-mBC-Informs-Clinical-Decision-Making/37332/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Comprehensive-Biomarker-Testing-in-mBC-Informs-Clinical-Decision-Making/37332/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

In today's episode, we had the pleasure of speaking with Stephen Liu, MD, about the use of tepotinib (Tepmetko) in patients with metastatic non–small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. Dr Liu is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC. In our exclusive interview, Dr Liu discussed key efficacy and safety findings from the phase 2 VISION trial (NCT02864992) that led to the FDA approval of tepotinib for this indication; the comparable response rates seen between tissue and liquid biopsy results, as well as across NSCLC treatment lines; and the importance of early biomarker testing, including RNA sequencing, to identify actionable mutations and optimize treatment.

Are you up to date on the latest laboratory tests for the diagnosis of rheumatoid arthritis (RA)? Hear the latest from the experts! Credit available for this activity expires: 9/29/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/diagnosing-rheumatoid-arthritis-early-integrating-serologic-2025a1000pl1?ecd=bdc_podcast_libsyn_mscpedu

Drs. Liu and Scott discuss the future of small cell lung cancer treatment, reviewing emerging strategies including immunotherapy, antibody–drug conjugates (ADCs), and bispecific T-cell engagers, as well as other targeted agents.

Have you ever wondered: What if, in those early days after diagnosis, there was something you could do to help protect the insulin your body still makes? In this episode, we're exploring exactly that. I'm joined by Ulf Hannelius, CEO of Diamyd Medical, to talk about a therapy that could be a game-changer for people newly diagnosed with type 1 diabetes. It's called GAD therapy, and it's currently being studied in the DIAGNODE-3 clinical trial. We dig into the science behind this investigational treatment and the hope it offers for preserving the body's remaining insulin production. Ulf not only explains the research in simple terms, but also shares his vision for the future of T1D. We know how overwhelming diabetes research can feel, but this is one conversation everyone in the T1D community should hear, especially if you or someone you love is facing a new diagnosis.Quick Takeaways:The latest research aiming to protect insulin production after a type 1 diabetes diagnosisA clear breakdown of Diamyd Medical's GAD therapy and the DIAGNODE-3 trial — what it is, who it's for, and why it offers hope for the future of T1DWhat's actually happening inside the body of someone newly diagnosed with type 1 diabetesDefining T1D terms you've probably heard but no one ever defines: Honeymoon phase, C-peptide, Stage 3 Type 1 Diabetes, Antigen-specific therapy, GAD65 + more 

Drs. Chaichian and Dall'Era explore the “treat to target” approach in lupus, including key targets like DORIS remission and lupus low disease activity state.

This conversation is with men's fertility expert Josh Paigen — whose path took him from a childhood fascination with the natural world to helping men and couples prepare for healthy conception. We explore the alarming global decline in sperm count, why preconception health is about far more than simply being able to conceive, and Josh's five pillars of male fertility: sustenance, purity, exercise, rest, and mindset. Along the way, we dive into the roles of nutrition, environmental toxins, circadian rhythms, and even inherited trauma in shaping reproductive health — and how small, intentional lifestyle shifts can have a profound impact on future generations.You can expect to learn• Why sperm count is plummeting (and why this matters)• Five pillars of male fertility you can start today• How diet, toxins, and lifestyle shape reproductive health• Sleep, stress, and mindsets' hidden role in fertility• Epigenetics: how trauma and health choices get passed on• Simple changes that can boost fertility and overall vitality[Timestamps]05:43 Understanding Preconception Health11:54 Sperm as a Biomarker for Health17:27 Nutrition and Sperm Health23:50 Understanding Everyday Toxins29:22 Minimizing EMF Exposure38:19 Circadian Rhythms and Hormonal Balance47:56 Mindset and Holistic Health55:35 The Interconnection of Health and Fertility01:00:58 Understanding Epigenetics and Trauma01:08:36 Challenging Myths in FertilityConnect with Josh

In today's episode, we had the pleasure of speaking with Balazs Halmos, MD, MS, about the phase 2 VISION trial (NCT02864992) evaluating tepotinib (Tepmetko) in patients with MET exon 14 skipping mutation–positive non–small cell lung cancer (NSCLC). Dr Halmos is a professor in the Department of Oncology (Medical Oncology) and the Department of Medicine (Oncology and Hematology), director of Thoracic Oncology, and associate director of Clinical Science at Montefiore Einstein Comprehensive Cancer Center in Bronx, New York. In our exclusive interview, Halmos discussed the rationale and design of the VISION trial, the significance of MET exon 14 skipping mutations as a distinct oncogenic driver, and the clinical utility of tepotinib, which is a selective MET TKI. He reviewed the trial's efficacy results, which demonstrated consistent response rates across lines of therapy and diagnostic methods, as well as tolerability findings that highlighted the importance of monitoring and managing MET-related adverse effects. Dr Halmos also reflected on subgroup analyses from the trial, noting the agent's activity across treatment settings, particularly in older patients and those with central nervous system involvement. Additionally, Halmos underscored the critical role of comprehensive biomarker testing in NSCLC, highlighting how parallel tissue- and circulating tumor DNA–based testing can optimize timely identification of actionable alterations and ensure patients receive the most effective frontline therapy. He also discussed practical considerations for dose selection and modifications with tepotinib, offering insights into strategies for maximizing treatment benefit and maintaining patient quality of life.

Eine individualisierte Diagnose ermöglicht Krebspatient:innen eine effektive und schonende Therapie. Doch obwohl die Biotech-Forschung in den letzten Jahren immer wieder große Durchbrüche erzielt hat, kommt davon im Kliniklabor oft nur wenig an - oder viel zu spät. Unsere heutige Gesprächspartnerin, Molekularbiologin und Unternehmerin Dr. Christina Port, hat sich am Anfang ihrer Gründungsreise die Frage gestellt, wie sie diese Lücke zwischen Forschung und klinischer Anwendung schließen kann. Mit ihrem Startup 2NA FISH entwickelte sie eine Plattform, die RNA-Veränderungen im räumlichen Gewebekontext sichtbar macht und so eine differenzierte Diagnose und Behandlung ermöglicht. In der Forschung ist der Ansatz bereits seit Jahren etabliert – doch fehlte es bisher an Verfahren, die ohne teure Spezialgeräte auskommen. Mit KI-unterstützer DNA-Nanotechnologie macht 2NA FISH die Cutting-Edge-Methode jetzt auch für Kliniken erschwinglich. Für diesen Ansatz wurde das Startup bereits mehrfach prämiert, unter anderem mit dem Gründungspreis des Bundeswirtschaftsministeriums. In dieser Podcast-Folge erfahrt ihr, wie aus jahrelanger Laborarbeit ein marktreifes Produkt erwachsen ist und warum die Gründerin auf klare Workflows und frühe Nutzerintegration setzt. Port berichtet von ihrer Entscheidung, auf eine akademische Karriere zu verzichten, und wie sie es geschafft hat, mit Unsicherheit umzugehen. Wir sprechen auch über praktischen Themen der Unternehmensgründung: Funding, Förderprogramme und die Frage, wie man ein Team nicht nur richtig stafft und führt, sondern auch bei Laune hält. Wer wissen will, wie Deep Tech mit ganz viel Expertise, Mut und einer Prise Zufall in echten Patientennutzen übersetzt wird, sollte unbedingt reinhören. Unsere neue Folge bietet eine spannende Mischung aus wissenschaftlicher Tiefe und authentischer -Gründerinnen-Erfahrung.

Dr. Ben Thompson joins Longevity Junkie to expose the silent link between hearing loss and dementia. From noise exposure to sound therapy, this episode breaks the myths and lays out proven strategies. This deep dive explains what really works for treatment and prevention.Get started with Treble Health:Schedule a complimentary telehealth consultation: treble.health/free-telehealth-consultation Take the tinnitus quiz: https://treble.health/tinnitus-quiz-1Download the Ultimate Tinnitus Guide: 2024 Edition: https://treble.health/tinnitus-guide-2024

Klinisch Relevant ist Dein Wissenspartner für das Gesundheitswesen. Drei mal pro Woche, nämlich dienstags, donnerstags und samstags, versorgen wir Dich mit unserem Podcast und liefern Dir Fachwissen für Deine klinische Praxis. Weitere Infos findest Du unter https://klinisch-relevant.de

Timestamps:6:00 - Tackling the early detection of sepsis 17:17 - Why obsess over hard challenges?27:41 - Marketing a new biomarker 34:20 - Expanding and delegating to distributors  This episode was co-produced with Innovaud, the innovation and investment promotion agency for the canton of Vaud.About Patrick Pestalozzi & François Capel:Patrick Pestalozzi is a former management consultant and Silicon Valley executive with 3 decades of global experience, most recently as the Vice-President of Global Strategic Accounts for Mindmaze and as the CEO at GaitUp, a Mindmaze subsidiary. In 2024 he became the CEO at Abionic, a medtech EPFL spin-off founded back in 2010.François Capel is an Innovation Director with 10+ years of experience driving innovation within fast-paced environments and innovation-driven industries. He is currently a full-time advisor at Innovaud, the innovation and investment promotion agency for the canton of Vaud.During his chat with Merle and François, Patrick shared his experience as Abionic CEO. Abionic is on a mission to transform sepsis diagnoses through the use of nanofluids, and their flagship product, abioSCOPE®, a near-patient rapid diagnostic platform, delivers lab-quality results from a drop of blood within minutes, providing valuable clinical insights and actionable information at the point-of-care.Don't forget to give us a follow on⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠ TikTok⁠⁠⁠⁠⁠⁠⁠⁠, and⁠⁠⁠⁠⁠⁠⁠⁠ Youtube ⁠⁠⁠⁠⁠⁠⁠⁠so you can always stay up to date with our latest initiatives. That way, there's no excuse for missing out on live shows, weekly giveaways or founders' dinners.

Welches Organ ist meine Schwachstelle? Wie jung ist mein Körper? Wie können wir gesund alt werden? Das biologische Alter beschäftigt uns je länger, je mehr. Genau da setzt der Schweizer Forscher Tony Wyss Coray an. Er kann mit einem neuen Verfahren das Alter der einzelnen Organe feststellen. Der Bluttest Als erste Person in der Schweiz macht Tobias Müller einen Test, welcher das Alter seiner Organe bestimmt. Dabei wird untersucht, welche organspezifischen Proteine im Blut aktiv sind und welche Konzentration sie aufweisen. Ist ein Organ älter als das chronologische Alter besteht ein erhöhtes Erkrankungsrisiko für das entsprechende Organ. Studien haben gezeigt, dass jeder fünfte Mensch über 50 Jahre mindestens ein Organ hat, das signifikant über dem chronologischen Alter liegt. Erste Studien Den Test hat der Forscher Tony Wyss-Coray entwickelt. Der Schweizer forscht und lehrt an der Eliteuniversität Stanford in den USA. Ursprung seiner Forschung war ein Experiment mit Mäusen, das in der Schweiz nicht genehmigt wurde. Dabei wurden eine junge und eine alte Maus aneinandergenäht. Das junge Blut hat die Organe der älteren Maus verjüngt und umgekehrt. Biomarker im Blut Heute kennen Tony Wyss-Coray und seine Kolleginnen Tausende Proteine, die sie einem spezifischen Organ zuweisen können. Aufgrund der Zusammensetzung des Blutes können die Forschenden das Alter jedes Organs schätzen. Wenn die Mediziner sehen, dass ein Organ schneller altert, ist das eine Zusatzinformation, die bislang in der Medizin noch nicht zur Verfügung steht. So kann man genauer und tiefer hinschauen und dann die Empfehlungen so gestalten, dass man frühzeitig reagieren kann, bevor sich strukturelle Veränderungen einstellen. Neuer Campus in Basel In Basel eröffnen Tony Wyss-Coray und die Chefärztin und Heike A. Bischoff-Ferrari einen Campus für eine gesunde Langlebigkeit im Felix-Platter-Spital. Dort sollen Menschen überprüfbare und bestätigte Daten zu ihrem Alter erhalten. Parallel wird auch die Forschung für eine gesunde Altersmedizin vorangetrieben.

Can stress actually improve flower quality? In this episode, I sit down with Dr. José Leme to dive into the science of plant stimuli and how growers can apply it in practice. We cover:

Featuring an interview with Dr Shannon N Westin, including the following topics: Biomarker testing and utility in ovarian cancer (OC) (0:00) Selection of a PARP inhibitor for the treatment of OC (9:18) Addition of immunotherapy to up-front treatment of OC (15:50) Utility of minimal residual disease and circulating tumor DNA assays in OC (17:10) Selection of treatment for recurrent OC (21:46) Clinical decision-making involved with PARP inhibitors for endometrial cancer (EC) (28:22) Adjuvant therapy for EC (32:28) Utility of lenvatinib/pembrolizumab in EC (35:08) Clinical findings supporting the potential use of selinexor for EC (39:42) Key findings involving trastuzumab deruxtecan (T-DXd) for HER2-positive gynecologic cancers (43:22) Management of adverse effects associated with T-DXd (49:49) CME information and select publications

How confident are you navigating biomarker conversations with your gastric cancer patients? Credit available for this activity expires: 8/19/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002840?ecd=bdc_podcast_libsyn_mscpedu

This episode originally dropped on February 12, 2025.Bill Campbell, PhD, has spent his entire career as a fat loss researcher. So when his wife hit menopause and wanted help with body composition changes, he thought it would be easy. Spoiler alert: It was not. Which made him realize his field had a lot to learn, especially about active women whose bodies change even when their training and nutrition has not. Now he's on a mission, diving into the literature and conducting research of his own to further our understanding of body composition changes during this time of life. We talk all about it, what he's learned, and his work developing a Female Fitness Menopause Survey to learn more.Bill Campbell, PhD is a Professor of Exercise Science and Director of the Performance and Physique Enhancement Laboratory at the University of South Florida. He is also a Certified Strength & Conditioning Specialist from the National Strength & Conditioning Association and former president of the International Society of Sports Nutrition (where he is also 1 of 35 individuals to be recognized as a ‘Fellow' of the organization—an honor reserved for those individuals who have outstanding contributions to the field of sports nutrition). He has published over 200 scientific papers and abstracts, three textbooks, and 20 book chapters in areas related to physique enhancement, sports nutrition, resistance training, and dietary supplementation. You can learn more about him and his work at www.billcampbellphd.comResourcesEstrogen modulates metabolic risk profile after resistance training in early postmenopausal women: a randomized controlled trial, hereTransdermal Estrogen Therapy Improves Gains in Skeletal Muscle Mass After 12 Weeks of Resistance Training in Early Postmenopausal Women, hereMetabolic effects of menopause: a cross-sectional characterization of body composition and exercise metabolism, herePowerpenia Should be Considered a Biomarker of Healthy Aging, herePurchase the Menopause Course Bundle and Save $111! https://learning.feisty.co/ Sign up for our FREE Feisty 40+ newsletter: https://feistymedia.ac-page.com/feisty-40-sign-up-page Follow Us on Instagram:Feisty Menopause: @feistymenopause Hit Play Not Pause Facebook Group: https://www.facebook.com/groups/807943973376099 Support our Partners:Hettas: Use code FEISTY20 for 20% off at https://hettas.com/ Midi Health: You Deserve to Feel Great. Book your virtual visit today at https://www.joinmidi.com/ Previnex: Get 15% off your first order with code HITPLAY at https://www.previnex.com/ This podcast uses the following third-party services for analysis: Spotify Ad Analytics - https://www.spotify.com/us/legal/ad-analytics-privacy-policy/Podcorn - https://podcorn.com/privacyPodscribe - https://podscribe.com/privacy

“Next-generation sequencing, or NGS, can be used to help us determine if the patient has specific biomarkers we can identify and use to target for treatment. Certain findings can tell us if a particular treatment might work for that patient, and we can see if there are any genetic variants we might have a biomarker targeted agent to use to treat them with,” ONS member Jackie Peterson, MSN, RN, OCN®, NE-BC, MBA, ambulatory nurse manager at the University of Chicago Medical Center in Illinois, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about prostate cancer and biomarker testing.  This podcast is sponsored by AstraZeneca and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod    Licensed under Creative Commons by Attribution 3.0   Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 180: Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care ONS Voice articles: An Oncology Nurse's Guide to Cascade Testing Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Disorders Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Germline and Somatic Variants: What Is the Difference? Help Patients Understand Genomic Variants of Unknown Significance Prostate Cancer Clinical Trials Don't Reflect Racial Diversity—And It's Getting Worse Over Time Prostate Cancer Disparities Disappear With Equal Access to Care Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations The Case of the Genomics-Guided Care for Prostate Cancer ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing articles: Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management Prostate Cancer: How Nurse Practicioners Can Aid in Disease Diagnosis and Management Oncology Nursing Forum article: Identification of Symptom Profiles in Prostate Cancer Survivors Other ONS Resources: Biomarker Database (refine by prostate cancer or specific biomarkers) Clinical tool/case study: Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Genomics and Precision Oncology Learning Library Huddle Card: Genomic Biomarkers Infographic: Talking to Your Patient About a Germline Variant of Uncertain Significance (VUS) American Cancer Society - Genetic Testing and Counseling for Prostate Cancer Risk American Cancer Society - Prostate Cancer Clinicaltrials.gov National Cancer Institute - Prostate Cancer National Comprehensive Cancer Network ZERO Prostate Cancer To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode “Some of the risk factors for developing prostate cancer include age, race, family history, and certain genetic changes or variants. Prostate cancer has some hereditary components, but most prostate cancer occurs in men without any significant family history of it.” TS 1:31 “Key biomarkers include PSA and prostate cancer gene 3, which is PCA3, and prostate-specific membrane antigen, or PSMA. Other biomarkers that are important for us to test include BRCA1, BRCA2, and Lynch syndrome–associated genes, which are MLH1, MSH2, MSH6, PMS2, and EPCAM. Biomarkers can be collected via your blood, urine, saliva, or tissue samples, so these are different ways that we can test and look for biomarkers in our patients.” TS 3:24 “It does matter how advanced the disease is. Usually, for our castrate-sensitive patients, they respond better to androgen deprivation therapy because that really is slowing down the growth of the cancer by reducing the available testosterone that the cancer needs to grow. Whereas our patients that are more advanced and have castrate-resistant prostate cancer, that cancer will continue to grow despite having the lowered testosterone levels, so they might need additional layers of treatment to really get their cancer under control.” TS 7:50 “When I talk to [patients] about biomarker testing, I tell them it's another tool in our toolbox that we can use to help us determine if they might benefit from other therapy options now or in the future. I tell them that sometimes we'll get a report back with a variant of unknown significance, and basically that means that we don't really know whether or not this has an impact on their health or risk factors for the disease. That can sometimes be a little bit of a concern for these patients, so we just have to reassure them that we're continually doing research around biomarker testing. The science is always advancing, so if there's something that [researchers] find in the future, we'll make them aware of that.” TS 9:08 “One of the biggest topics I think about is the inequity that exists in biomarker testing and research, especially surrounding the African American population. When these tests were developed, that population really wasn't studied as much, so there's not a lot of good data yet to make a decision or impact on those patients and that population.” TS: 12:30

Mauro Stara is the founder of Six Pack CEO and a peak-performance strategist for time-pressed leaders. Drawing on his background in banking and a science‑driven approach that starts with deep biomarker analysis, Mauro helps CEOs resolve hidden hormonal roadblocks, build cover‑model physiques, and unlock the energy they need to scale their companies without sacrificing health or family life.   https://www.linkedin.com/in/mauro-stara-4b4295217/ https://www.instagram.com/maurostaraofficial/   This podcast is brought to you by LMNT Electrolytes! It's great for a hot summer day, a workout, or just working at your desk with cold water. Check it out and get your free sample pack along with any regular purchase when you use my custom link, www.drinklmnt.com/ScottMys. The LMNT Sample Pack includes one packet of their most popular flavors. This is the perfect offer for 1) anyone who is interested in trying all of our flavors or 2) anyone who wants to introduce a friend to LMNT. Go to www.drinklmnt.com/ScottMys to claim this awesome deal!   Interested in working with me 1-1? I offer personalized coaching where I can help you reach your goals whether it be fat loss, muscle building, health improvements, or all of the above. I provide tailored nutrition, training, and supplementation advice (one or all together) with 24/7 ongoing support to help guide you every step of the way. DM me on Instagram and I can answer any questions. If you like, we can even set up a FREE consult call to go over your goals, answer questions, and discuss what it could look like to work together!

Howie and Harlan are joined by Azita Emami, dean of the Yale School of Nursing, to discuss the school's approach to training nurses who can have a seat at the table of healthcare decision-making. Harlan reports on his new study showing the low levels of evidence required for medical devices in the FDA's Breakthrough Devices Program; Howie provides some good news about infectious diseases including malaria and HIV. Links: Breakthrough devices? Harlan Krumholz: “FDA Authorization of Therapeutic Devices Under the Breakthrough Devices Program” FDA: Breakthrough Devices Program “Many medical devices deemed ‘breakthrough' by FDA are backed by patchy evidence” FDA Facts: Biomarkers and Surrogate Endpoints Harlan Krumholz: “Class I Recalls of Cardiovascular Devices Between 2013 and 2022 : A Cross-Sectional Analysis” Azita Emami “Americans' Ratings of U.S. Professions Stay Historically Low” “University of Washington selects Azita Emami as dean of School of Nursing” “Azita Emami named new dean of School of Nursing” “The Report of the Rockefeller Foundation on Nursing Education: A Review and Critique” Cleveland Clinic: DHEAS Test “DHEA as a Biomarker of Stress: A Systematic Review and Meta-Analysis” Azita Emami: “Assessing stress using repeated saliva concentration of steroid hormones in dementia care dyads: results from a controlled pilot care music intervention” Azita Emami: “The Feasibility and Acceptability of In-Home Saliva Collection for Stress in Persons With Dementia and Their Family Caregivers” Infectious diseases Mayo Clinic: Malaria WHO: World Malaria Report 2024 “Georgia certified malaria-free by WHO” “Suriname certified malaria-free by WHO” The Global Fund to Fight AIDS, Tuberculosis and Malaria “Novartis wins approval for first malaria drug for newborns and babies” “FDA Approves a Twice-Yearly Shot to Prevent HIV” “U.S. measles cases hit highest level in 33 years, CDC reports” Texas Department of State Health Services: Measles Outbreak “The West Texas measles outbreak has started to slow for the first time since January” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

In this episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was rejoined by Midhun Malla, MD, of the University of Alabama at Birmingham, to discuss therapeutic options for patients with metastatic colorectal cancer (mCRC), particularly in the third-line setting and beyond. In the final part of this 3-part episode miniseries, Drs Park and Malla explored the challenges faced by community oncologists, especially in rural or underserved areas, in accessing clinical trials, which remain a preferred disease management approach due to their role in advancing novel therapies. However, in the absence of trial availability or when patients are ineligible, they emphasized the importance of evidence-based, FDA-approved agents for later lines of therapy. Three primary agents were discussed for patients who have progressed on first-line FOLFOX (folinic acid, fluorouracil, and oxaliplatin) and second-line FOLFIRI (folinic acid, fluorouracil, and irinotecan) regimens: trifluridine/tipiracil (TAS-102; Lonsurf) plus bevacizumab (Avastin); fruquintinib (Fruzaqla); and regorafenib (Stivarga). These agents offer viable treatment pathways in biomarker-unselected patient populations. However, direct comparisons between these agents are lacking, as most were tested against placebo controls. The choice among them is often individualized based on patient performance status, prior exposure to biologics, and toxicity profiles. TAS-102 plus bevacizumab has generated promising results, though real-world data may show diminished efficacy due to frequent prior exposure to 5-fluorouracil and bevacizumab in US patients. Fruquintinib offers a VEGF-targeted approach with a more favorable hematologic toxicity profile, whereas regorafenib is associated with notable adverse effects, including hypertension, gastrointestinal toxicity, and mucositis. Park and Malla emphasized the importance of treatment sequencing, toxicity management, and individualized patient-centered care, including consideration of dose modifications to preserve quality of life in later-line settings. In addition to later-line options, the conversation also touched on emerging frontline therapies. Notable investigational agents include zanidatimab-hrii (Ziihera) and KRAS G12C–directed therapies. Additionally, a novel integrin-targeted cytotoxin is currently under evaluation at the University of Alabama at Birmingham in patients with treatment-naive mCRC. This agent induces apoptosis via caspase-8 activation and has demonstrated encouraging preclinical activity. Overall, the discussion highlighted a nuanced, biomarker-informed, and patient-tailored approach to mCRC management, emphasizing both the value of clinical trials and the importance of optimizing currently available therapies.

Tired of overpriced marketing tools? Omnisend gives you pro-level automation without draining your wallet. Try it here and see why I made the switch: https://your.omnisend.com/codiesanchez30 Codie and Dr. Rena Malik discuss the complexities of female orgasm, the myths surrounding male sexual performance, and the dynamics of libido in relationships. They delve into the complexities of sexual education, the impact of pornography on young people's understanding of sex, and the importance of open communication between parents and children. The discussion also touches on the future of intimacy in the age of AI and the importance of maintaining human connection. Chapters 00:00 Intro 12:49 The Myths of Male Sexual Performance 26:02 Navigating Libido and Sexual Desire in Relationships 31:17 The Impact of Porn on Sexual Education 35:04 Navigating Conversations About Sex with Kids 39:53 Exploring Personal Sexuality and Preferences 42:55 Sex as a Biomarker of Overall Health 45:51 The Changing Landscape of Sexual Relationships 48:32 Understanding the Pelvic Floor 53:37 The Role of Substances in Sexual Experience 01:00:04 The Future of Intimacy and AI MORE FROM BIGDEAL:

Let's be honest, perimenopause and menopause are incredibly transformative journeys that NONE of us asked for. So, it's up to us to find meaning and purpose amid these shifts.  That's what this episode is all about– finding the power you hold to understand what's really happening in your body at this stage of life.  It's time to decode the symptoms you've been told to brush off again and again by your doctor, and take ACTION that changes your health trajectory today, and for all your days to come. In this episode, I'll provide you with the framework for understanding your body in perimenopause and help you take actionable steps to feel more alive and achieve the results you deserve. We're diving into labs, biomarkers, and how to harness this data to become the ultimate CEO of your health, feeling more confident in your body every day. Tune in here and discover how to reclaim your story and feel empowered every step of the way!  IN THIS EPISODE Why your metabolic health is key to your overall wellness  The 5 biomarkers of optimal metabolic health  Navigating the massive knowledge gap in our healthcare system How to avoid chronic complications down the road  The three truths you need to know about your metabolic health  Understanding your specific lab ranges and analyzing your results  Action steps to find out if you're metabolically healthy  QUOTES “88% of women over 45 years old will have some level of metabolic dysfunction, and insulin resistance is really the silent force behind 8 out of the 10 top causes of death in the US.”  “Metabolic dysfunction and syndrome occur when three or more of the following biomarkers are out of range.” “What a lot of us don't realize is the things that are manifesting in our sixties and seventies really started in our forties. And often they could have been avoided with earlier, more targeted interventions.” RESOURCES MENTIONED The Perimenopause Revolution by Dr. Mariza Snyder: Pre-order your copy here and get IMMEDIATE ACCESS to bonuses like The Perimenopause Power Toolkit, workout videos, recipes & more!  www.qualialife.com/drmariza, Coupon Code: ENERGIZED BEAM Minerals: Use code ENERGIZED at checkout for 20% off your first order! RELATED EPISODES  #648: This Changes Everything: The Perimenopause Revolution Every Woman Needs Now 595: How to Master Your Metabolism and Reverse Cellular Aging in Midlife + My Best Tips to Thrive with Dr. Mariza 584: The Health Costs of Our Modern Life & How to Start Feeling Better with Dr. Casey Means #541: Why Functional Labs Are a Game Changer for Your Health with Dr. Kela Smith

Levels offers biomarker testing to give you more insight into your health status so you can understand the root causes of your symptoms, take a preventive approach to disease, and see if your lifestyle changes or other interventions are reducing your risk factors and improving your health. Dr. Anjali Dsouza and Mike Haney discuss why biomarker testing can be beneficial, how to understand your levels, factors that affect your levels, and which biomarkers are no-brainers to get tested.Sign Up to Get Your Free Ultimate Guide to Glucose: ⁠⁠⁠⁠⁠⁠⁠https://levels.link/wnl⁠⁠⁠⁠⁠⁠Levels helps you see how food affects your health, empowering you with the tools needed to achieve health goals and improve healthspan. Levels Members gain access to the Levels app and continuous glucose monitors (CGMs), providing real-time feedback on how diet and lifestyle choices impact your metabolic health.Look for new shows every month on A Whole New Level, where we have in-depth conversations with thought leaders about metabolic health.

Naked Gardening Best Cities… NJ Wildfire update and an arson arrest… AJ Brown car (whip) stolen… Jack in the Box closing hundreds of stores…Shannon Sharpe steps away from ESPN… NFL Draft Update… Email: ChewingTheFat@theblaze.com Sperm Race in LA… Blake Lively / Baldoni case ongoing... Golden Globes date... Academy rule changes…www.blazetv.com/jeffy Promo code Jeffy… Mortuary lady testing on bodies… No kidding, Jersey Mike's has new CEO… Game Show: What's The Lie? Family edition / Contestants: Dean & Wesley Castelhano… Learn more about your ad choices. Visit megaphone.fm/adchoices